Miraculins is a medical diagnostic development company focused on non-invasive tests for unmet clinical needs. Miraculins is bridging the gap between research conducted at leading research institutions around the world and commercially available diagnostic tests.
The Company’s lead product is a serum based diagnostic being developed for preeclampsia, a devastating disease of pregnancy, based on a suite of markers discovered by leading researchers at Mount Sinai Hospital and the Hospital for Sick Children.
For more information, please contact:
Christopher J. Moreau, President & Chief Executive Officer cmoreau@miraculins.com
(204) 477-7599
6-1250 Waverley Street, Winnipeg, MB, Canada, R3T 6C6
This page made possible by LSAM's exclusive sector directory sponsor.
